Pegfilgrastim-Jmdb: uses, dosing, side effects & brands
Pegfilgrastim-Jmdb is a medicine sold in the U.S. under one brand, for neutropenia. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Treats
- Neutropenia
- Available as
- Injectable
- Sold as
- Fulphila
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How pegfilgrastim-jmdb is dosed
From the FDA label for Fulphila (application BLA761075). Other pegfilgrastim-jmdb products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Patients with cancer receiving myelosuppressive chemotherapy • 6 mg administered subcutaneously once per chemotherapy cycle. ( 2.1 ) • Do not administer between 14 days before and 24 hours after administration of cytotoxic chemotherapy. ( 2.1 ) • Use weight based dosing for pediatric patients weighing less than 45 kg; refer to Table 1. ( 2.2 ) 2.1 Patients with Cancer Receiving Myelosuppressive Chemotherapy The recommended dosage of Fulphila is a single subcutaneous injection of 6 mg administered once per chemotherapy cycle. For dosing in pediatric patients weighing less than 45 kg, refer to Table 1. Do not administer Fulphila between 14 days before and 24 hours after administration of cytotoxic chemotherapy. 2.2 Administration Fulphila is administered subcutaneously via a single-dose prefilled syringe for manual use. Prior to use‚ remove the carton from the refrigerator and allow the Fulphila prefilled syringe to reach room temperature for a minimum of 30 minutes. Discard any prefilled syringe left at room temperature for greater than 72 hours. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer Fulphila if discoloration or particulates are observed. Pediatric Patients weighing less than 45 kg The Fulphila prefilled syringe is not designed to allow for…
Pegfilgrastim-Jmdb side effects
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: • Splenic Rupture [See Warnings and Precautions (5.1) ] • Acute Respiratory Distress Syndrome [See Warnings and Precautions (5.2) ] • Serious Allergic Reactions [See Warnings and Precautions (5.3) ] • Use in Patients with Sickle Cell Disorders [See Warnings and Precautions (5.4) ] • Glomerulonephritis [See Warnings and Precautions (5.5) ] • Leukocytosis [See Warnings and Precautions (5.6) ] • Thrombocytopenia [See Warnings and Precautions (5.7) ] • Capillary Leak Syndrome [See Warnings and Precautions (5.8) ] • Potential for Tumor Growth Stimulatory Effects on Malignant Cells [See Warnings and Precautions (5.9) ] • Myelodysplastic syndrome [See Warnings and Precautions (5.10) ] • Acute myeloid leukemia [See Warnings and Precautions (5.10) ] • Aortitis [see Warnings and Precautions (5.11) ] Most common adverse reactions (≥ 5% difference in incidence compared to placebo) are bone pain and pain in extremity. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Biocon Biologics Inc. at 1-833-986-1468 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . *Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that…
Who shouldn’t take pegfilgrastim-jmdb
Fulphila is contraindicated in patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products. Reactions have included anaphylaxis [see Warnings and Precautions (5.3) ] . Patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors such as pegfilgrastim products or filgrastim products. ( 4 )
Every pegfilgrastim-jmdb product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Fulphila.
What people report to the FDA about pegfilgrastim-jmdb
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 13 reports naming pegfilgrastim-jmdb, and the FDA flagged 92% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- hypoxia3 reports
- pyrexia3 reports
- alopecia2 reports
- anxiety2 reports
- malignant neoplasm progression2 reports
- platelet count decreased2 reports
- prostatic specific antigen increased2 reports
- abdominal pain1 reports
Read these as a signal, not a rate. A report does not mean pegfilgrastim-jmdb caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is pegfilgrastim-jmdb?
Fulphila (Pegfilgrastim-Jmdb) is a medication used to treat Neutropenia.
Can you take pegfilgrastim-jmdb with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run pegfilgrastim-jmdb against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does pegfilgrastim-jmdb come in?
Across the brands we track, pegfilgrastim-jmdb is currently marketed as injectable, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic pegfilgrastim-jmdb?
We do not currently list a generic-labelled pegfilgrastim-jmdb product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Pegfilgrastim-Jmdb: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/pegfilgrastim-jmdb
- MLA
- “Pegfilgrastim-Jmdb: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/pegfilgrastim-jmdb.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for pegfilgrastim-jmdb on DailyMed (NIH) ↗.